AbbVie, Janssen's $3B Imbruvica Faces First Generic Threat
Patent infringement litigation is undoubtedly on the horizon for Natco and Alvogen after the drugmakers said Thursday that they've asked the U.S. Food and Drug Administration to approve their generic version...To view the full article, register now.
Already a subscriber? Click here to view full article